Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
53
AXIM Quote, Financials, Valuation and Earnings
Last price:
$0.0200
Seasonality move
:
5.9%
Day range:
$0.0215 - $0.0220
52-week range:
$0.0013 - $0.0288
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
127.90x
P/B ratio:
--
Volume:
510.5K
Avg. volume:
429.1K
1-year change:
714.81%
Market cap:
$7.3M
Revenue:
$70.5K
EPS (TTM):
-$0.02
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AXIM
AXIM Biotechnologies, Inc.
|
-- | -- | -- | -- | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.20 | -- | -26.67% | $7.00 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AXIM
AXIM Biotechnologies, Inc.
|
$0.0220 | -- | $7.3M | -- | $0.00 | 0% | 127.90x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.09 | $0.85 | $137.4M | 1.83x | $0.80 | 0% | 2.12x |
|
NNVC
NanoViricides, Inc.
|
$1.22 | $7.00 | $22M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.85 | $2.00 | $700.8K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.24 | $7.00 | $8.2M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AXIM
AXIM Biotechnologies, Inc.
|
-224.48% | -0.375 | 226.27% | 0.00x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AXIM
AXIM Biotechnologies, Inc.
|
-- | -$268.7K | -- | -- | -11619.41% | -$133.1K |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
AXIM Biotechnologies, Inc. vs. Competitors
-
Which has Higher Returns AXIM or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -12985.96% compared to AXIM Biotechnologies, Inc.'s net margin of -255.85%. AXIM Biotechnologies, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital AXIMAXIM Biotechnologies, Inc.90.02% -$0.00 -$2.9M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About AXIM or NBY?
AXIM Biotechnologies, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that NovaBay Pharmaceuticals, Inc. has higher upside potential than AXIM Biotechnologies, Inc., analysts believe NovaBay Pharmaceuticals, Inc. is more attractive than AXIM Biotechnologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AXIMAXIM Biotechnologies, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is AXIM or NBY More Risky?
AXIM Biotechnologies, Inc. has a beta of -0.613, which suggesting that the stock is 161.328% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock AXIM or NBY?
AXIM Biotechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. AXIM Biotechnologies, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXIM or NBY?
AXIM Biotechnologies, Inc. quarterly revenues are $17.5K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. AXIM Biotechnologies, Inc.'s net income of -$234.3K is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, AXIM Biotechnologies, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AXIM Biotechnologies, Inc. is 127.90x versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXIMAXIM Biotechnologies, Inc.127.90x -- $17.5K -$234.3K NBYNovaBay Pharmaceuticals, Inc.2.12x 1.83x $521K -$1.3M
-
Which has Higher Returns AXIM or NNVC?
NanoViricides, Inc. has a net margin of -12985.96% compared to AXIM Biotechnologies, Inc.'s net margin of --. AXIM Biotechnologies, Inc.'s return on equity of -- beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital AXIMAXIM Biotechnologies, Inc.90.02% -$0.00 -$2.9M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About AXIM or NNVC?
AXIM Biotechnologies, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand NanoViricides, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 473.77%. Given that NanoViricides, Inc. has higher upside potential than AXIM Biotechnologies, Inc., analysts believe NanoViricides, Inc. is more attractive than AXIM Biotechnologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AXIMAXIM Biotechnologies, Inc.0 0 0 NNVCNanoViricides, Inc.0 0 0 -
Is AXIM or NNVC More Risky?
AXIM Biotechnologies, Inc. has a beta of -0.613, which suggesting that the stock is 161.328% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock AXIM or NNVC?
AXIM Biotechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AXIM Biotechnologies, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXIM or NNVC?
AXIM Biotechnologies, Inc. quarterly revenues are $17.5K, which are larger than NanoViricides, Inc. quarterly revenues of --. AXIM Biotechnologies, Inc.'s net income of -$234.3K is higher than NanoViricides, Inc.'s net income of -$1.8M. Notably, AXIM Biotechnologies, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AXIM Biotechnologies, Inc. is 127.90x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXIMAXIM Biotechnologies, Inc.127.90x -- $17.5K -$234.3K NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns AXIM or OGEN?
Oragenics, Inc. has a net margin of -12985.96% compared to AXIM Biotechnologies, Inc.'s net margin of --. AXIM Biotechnologies, Inc.'s return on equity of -- beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital AXIMAXIM Biotechnologies, Inc.90.02% -$0.00 -$2.9M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About AXIM or OGEN?
AXIM Biotechnologies, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 134.85%. Given that Oragenics, Inc. has higher upside potential than AXIM Biotechnologies, Inc., analysts believe Oragenics, Inc. is more attractive than AXIM Biotechnologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AXIMAXIM Biotechnologies, Inc.0 0 0 OGENOragenics, Inc.1 0 0 -
Is AXIM or OGEN More Risky?
AXIM Biotechnologies, Inc. has a beta of -0.613, which suggesting that the stock is 161.328% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock AXIM or OGEN?
AXIM Biotechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AXIM Biotechnologies, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXIM or OGEN?
AXIM Biotechnologies, Inc. quarterly revenues are $17.5K, which are larger than Oragenics, Inc. quarterly revenues of --. AXIM Biotechnologies, Inc.'s net income of -$234.3K is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, AXIM Biotechnologies, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AXIM Biotechnologies, Inc. is 127.90x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXIMAXIM Biotechnologies, Inc.127.90x -- $17.5K -$234.3K OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns AXIM or PTN?
Palatin Technologies has a net margin of -12985.96% compared to AXIM Biotechnologies, Inc.'s net margin of --. AXIM Biotechnologies, Inc.'s return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AXIMAXIM Biotechnologies, Inc.90.02% -$0.00 -$2.9M PTNPalatin Technologies-- -- -- -
What do Analysts Say About AXIM or PTN?
AXIM Biotechnologies, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than AXIM Biotechnologies, Inc., analysts believe Palatin Technologies is more attractive than AXIM Biotechnologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AXIMAXIM Biotechnologies, Inc.0 0 0 PTNPalatin Technologies0 0 0 -
Is AXIM or PTN More Risky?
AXIM Biotechnologies, Inc. has a beta of -0.613, which suggesting that the stock is 161.328% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock AXIM or PTN?
AXIM Biotechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AXIM Biotechnologies, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXIM or PTN?
AXIM Biotechnologies, Inc. quarterly revenues are $17.5K, which are larger than Palatin Technologies quarterly revenues of --. AXIM Biotechnologies, Inc.'s net income of -$234.3K is higher than Palatin Technologies's net income of --. Notably, AXIM Biotechnologies, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AXIM Biotechnologies, Inc. is 127.90x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXIMAXIM Biotechnologies, Inc.127.90x -- $17.5K -$234.3K PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns AXIM or TOVX?
Theriva Biologics, Inc. has a net margin of -12985.96% compared to AXIM Biotechnologies, Inc.'s net margin of --. AXIM Biotechnologies, Inc.'s return on equity of -- beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital AXIMAXIM Biotechnologies, Inc.90.02% -$0.00 -$2.9M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About AXIM or TOVX?
AXIM Biotechnologies, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 2797.35%. Given that Theriva Biologics, Inc. has higher upside potential than AXIM Biotechnologies, Inc., analysts believe Theriva Biologics, Inc. is more attractive than AXIM Biotechnologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AXIMAXIM Biotechnologies, Inc.0 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is AXIM or TOVX More Risky?
AXIM Biotechnologies, Inc. has a beta of -0.613, which suggesting that the stock is 161.328% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock AXIM or TOVX?
AXIM Biotechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AXIM Biotechnologies, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AXIM or TOVX?
AXIM Biotechnologies, Inc. quarterly revenues are $17.5K, which are larger than Theriva Biologics, Inc. quarterly revenues of --. AXIM Biotechnologies, Inc.'s net income of -$234.3K is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, AXIM Biotechnologies, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AXIM Biotechnologies, Inc. is 127.90x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AXIMAXIM Biotechnologies, Inc.127.90x -- $17.5K -$234.3K TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 71.88% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is up 1.22% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is down 0.5% over the past day.
